CD226 and neoplasm: Furthermore, mice with a Y319F mutation in CD226, which abrogates recruitment of the E3 ubiquitin ligase CBL-B for ubiquitinylation and proteasomal degradation, exhibited increased CD226 expression on CD8+ T cells and suppressed tumor growth (28).